News Related to Rinvoq

Related coverage linked through entity extraction aliases.

AbbVie Reports Record Sales and Earnings Beat, Advances Clinical Pipeline

Feb 12, 2026

AbbVie reported stronger-than-expected Q4 revenue of $16.62 billion and EPS of $2.71, beating consensus estimates. The company advanced a toxin-based therapy in Phase 2 trials and filed suit challenging Medicare drug-price negotiations for Botox.

AbbVie Projects Strong 2026 Growth as Skyrizi and Rinvoq Replace Humira

Feb 13, 2026

AbbVie projects 43-45% earnings growth in 2026 as newer immunology drugs Skyrizi and Rinvoq offset declining Humira sales, while maintaining its 54-year dividend increase streak as a Dividend King.